SWOG clinical trial number
S9926
Phase II Study of Temozolomide in Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
Closed
Phase
Accrual
56%
Research committees
Sarcoma
Treatment
Temozolomide
Eligibility Criteria Expand/Collapse
Pts must have histologic or cytologic dx of GIST that is unresectable or metastatic. Pts. must have at least one measurable lesion by x-ray, scans (CT or MRI), ultrasound, or physical exam documented 28 days prior to registration. Zubrod PS 0-2. No prior chemo for this dz except for STI-571 as adjuvant therapy or tx for met dz. No prior or concomitant RT except palliative RT. Prior surgery is allowed if at least 4 wks have elapsed and pt has recovered from all side effects. Pts w/ uterin, retroperitoneal sarcomas on non-intraabdominal leioymosarcomas are not eligible.